On June 4, 2026, Veeva Systems Inc. (NYSE: VEEV) made headlines with a significant press release detailing advancements presented at the recently concluded Veeva R&D and Quality Summit Europe. The event, held from May 28-29 in Copenhagen, Denmark, brought together over 2,000 leaders from the life sciences industry, including prominent companies such as AOP Health, Boehringer Ingelheim, GSK, MSD, Novo Nordisk, Roche, and Sanofi.

1. Unveiling Veeva Falcon and Vault AI Innovations

Veeva Systems showcased its upcoming Veeva Falcon agentic labor platform, a groundbreaking development aimed at enhancing the efficiency of drug development processes. In addition, the company highlighted its Vault AI innovations, which are set to transform the industry by streamlining operations and establishing a scalable path for artificial intelligence (AI) integration.

Key Features of Veeva Falcon

The Veeva Falcon agentic labor platform aims to reduce costs, increase speed, and maintain compliance in drug development. Initial offerings, expected to be available to early adopters in late 2026, will focus on critical areas such as:

Trial Master File Document Intake and Quality Control

Health Authority Correspondence in Regulatory Affairs

Safety Case Triage and Intake

The planned release of Vault AI across all Vault applications is slated for August 2026, signaling a significant step toward AI-enabled life sciences operations.

2. Insights from Industry Leaders

The Veeva Summit featured over 100 sessions where leaders shared insights and success stories on various topics, including:

Accelerating Development and Manufacturing

AOP Health showcased how it has sped up development timelines through connected R&D, quality, commercial, and data operations using the Veeva Industry Cloud.

Merck KGaA discussed its strategies for optimizing data to create a robust foundation for AI and automation in regulatory processes.

Advancing Clinical and Site Collaboration

Boehringer Ingelheim presented its end-to-end clinical operations designed to foster better connections with sites and patients.

GSK outlined its efforts in standardizing site engagement to facilitate faster activation and enhance performance.

Collaborations between Boehringer Ingelheim and Roche focused on streamlining site payments and strengthening collaborations.

Novo Nordisk, along with Sobi and Syneos Health Consulting, emphasized the importance of full data ownership and clinical efficiency by linking electronic data capture (EDC) to clinical databases.

Modernizing Quality, Safety, and Compliance

Haleon and Sanofi are preparing for the integration of agentic AI in quality management, prioritizing efficiency gains.

Novo Nordisk is simplifying pharmacovigilance processes to enhance efficiency and manage global data more effectively.

UCB is modernizing system validation processes to ensure GxP readiness and continuous compliance.

3. Future of Life Sciences with AI

Rik van Mol, Senior Vice President of Veeva Development Cloud, emphasized the potential impact of the ideas shared at the summit, stating, "The ideas shared and connections made at Veeva Summit will extend far beyond the event to move the industry to an agentic future." The introduction of Vault AI and Veeva Falcon represents a significant leap toward AI-enabling life sciences for greater speed and efficiency.

4. Conclusion

The Veeva R&D and Quality Summit has positioned Veeva Systems at the forefront of innovation in the life sciences sector. As the company prepares to roll out its Falcon platform and Vault AI innovations, stakeholders can anticipate a transformative impact on drug development processes, compliance management, and overall operational efficiency.

For those eager to learn more about Veeva Falcon agentic labor, Vault AI, and other core Vault innovations, session replays are available on Veeva Connect.

Original press release